SABS

SAB Biotherapeutics, Inc. [SABS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SABS Stock Summary

Top 10 Correlated Stocks

SABS


In the News

08:00 29 Mar 2024 SABS

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 3:15 PM EST.

08:00 29 Mar 2024 SABS

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced Samuel J. Reich, the Company's Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 1:20 PM EST.

11:16 29 Mar 2024 SABS

Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Now

SAB Biotherapeutics, Inc. (SABS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

08:30 29 Mar 2024 SABS

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176 SAB Biotherapeutics President & Chief Executive Officer Eddie Sullivan, Ph.D. to present novel DiversitAb™ platform pipeline, with emphasis on partnering influenza therapeutic, SAB-176

05:00 29 Mar 2024 SABS

SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11

SIOUX FALLS, S.D., May 03, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human, multi-epitope binding immunoglobulin IgG1 (polyclonal) antibodies without the need for human donors, is pleased to announce that Eddie Sullivan, PhD, co-founder, President & CEO of SAB Biotherapeutics, will be presenting and hosting one-on-one meetings with investors at the upcoming Sidoti Virtual Investor Conference on May 10 at 11:30am ET. The presentation can be accessed live at: https://sidoti.zoom.us/webinar/register/WN_hky73f7PSt6rJa3TODNaAQ.

08:17 29 Mar 2024 SABS

Promising Upsides on these Biotech Penny Stocks

For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet profitable, but they offer the potential for high growth as their products gain regulatory approval and market acceptance.

12:44 29 Mar 2024 SABS

SAB Biotherapeutics up 80% after FDA grants fast-track status to flu therapeutic

SAB Biotherapeutics (NASDAQ:SABS) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational therapeutic SAB-176 for Type A and Type B influenza illness in high-risk patients, including those who have anti-viral resistant strains, causing the company's shares to shoot up more than 80%. A Fast Track designation allows drugmakers to expedite the development and review of medicines that target critical illnesses and address unmet medical needs.

08:30 29 Mar 2024 SABS

SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

SIOUX FALLS, S.D., Dec. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that SAB Biotherapeutics has been selected to present at the Biotech Showcase 2023 meeting, an investor conference that drives biotech innovation and global collaboration through presentations delivered by innovative biotech companies, face-to-face networking and one-to-one meetings. The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.

07:10 29 Mar 2024 SABS

SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

09:14 29 Mar 2024 SABS

SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study

Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.

SABS Financial details

Company Rating
Neutral
Market Cap
45.02M
Income
-27.26M
Revenue
4.09M
Book val./share
0.29
Cash/share
0.05
Dividend
-
Dividend %
-
Employees
56
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-11.42
Forward P/E
-1.39
PEG
10.07
P/S
1.43
P/B
20.4
P/C
92
P/FCF
0.87
Quick Ratio
0.26
Current Ratio
0.34
Debt / Equity
0.3
LT Debt / Equity
0.23
-
-
EPS (TTM)
-0.57
EPS next Y
-3.32
EPS next Q
-0.46
EPS this Y
-32.81%
EPS next Y
485.13%
EPS next 5Y
-3131.37%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
1381.98%
EPS Q/Q
-30.43%
-
-
-
-
SMA20
-3.73%
SMA50
-23.05%
SMA100
-52.85%
Inst Own
7.41%
Inst Trans
0.94%
ROA
-96%
ROE
-121%
ROC
-1.41%
Gross Margin
100%
Oper. Margin
-661%
Profit Margin
-666%
Payout
-
Shs Outstand
9.23M
Shs Float
7.48M
-
-
-
-
Target Price
3
52W Range
3.66-14.5
52W High
-67.14%
52W Low
+53.33%
RSI
42.74
Rel Volume
0.25
Avg Volume
18.38K
Volume
4.52K
Perf Week
-4.17%
Perf Month
-22.82%
Perf Quarter
-32.51%
Perf Half Y
-9.98%
-
-
-
-
Beta
0.789
-
-
Volatility
0.27%, 0.51%
Prev Close
9%
Price
4.6
Change
10.31%

SABS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0.081.272.230.55
Net income per share
-0.220.46-0.64-0.43
Operating cash flow per share
-0.210.230.140.09
Free cash flow per share
-0.23-0.06-0.26-0.17
Cash per share
0.150.291.210.35
Book value per share
-0.050.91.410.71
Tangible book value per share
-0.050.91.410.71
Share holders equity per share
-0.050.91.410.71
Interest debt per share
0.190.20.260.14
Market cap
4.41B4.41B2.14B256.75M
Enterprise value
4.41B4.41B2.11B247.64M
P/E ratio
-468.57219.34-122.4-13.7
Price to sales ratio
1.28K79.8935.0710.74
POCF ratio
-478.89441.06568.0868.31
PFCF ratio
-449.21-1.62K-297.17-35.73
P/B Ratio
-1.91K113.1255.398.27
PTB ratio
-1.91K113.1255.398.27
EV to sales
1.28K79.834.6410.36
Enterprise value over EBITDA
-536.04208.57-180.06-9.12
EV to operating cash flow
-479.03440.61561.0465.89
EV to free cash flow
-449.34-1.62K-293.49-34.47
Earnings yield
00-0.01-0.07
Free cash flow yield
000-0.03
Debt to equity
-3.310.210.170.19
Debt to assets
0.420.140.080.12
Net debt to EBITDA
-0.16-0.212.260.34
Current ratio
2.013.111.961.47
Interest coverage
-20.2443.82-45.48-95.89
Income quality
1.030.5-0.22-0.22
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
1.190.120.280.69
Research and developement to revenue
2.330.510.941.52
Intangibles to total assets
0000
Capex to operating cash flow
0.07-1.27-2.91-2.91
Capex to revenue
-0.18-0.23-0.18-0.46
Capex to depreciation
-1.88-23.23-6.62-6.62
Stock based compensation to revenue
0.110.020.040.1
Graham number
0.513.064.52.63
ROIC
-0.790.37-0.26-0.7
Return on tangible assets
-0.520.36-0.22-0.37
Graham Net
-0.270.24-0.06-0.01
Working capital
4.67M23.39M23.74M7.1M
Tangible asset value
-2.31M39.01M38.55M31.06M
Net current asset value
-11.02M16.92M7.6M2.25M
Invested capital
-3.310.210.170.19
Average receivables
011.69M14.29M6.78M
Average payables
04.78M5.92M4.07M
Average inventory
0000
Days sales outstanding
298.92135.9248.0384.85
Days payables outstanding
00984.13407.94
Days of inventory on hand
0000
Receivables turnover
1.222.697.64.3
Payables turnover
000.370.89
Inventory turnover
0000
ROE
4.080.52-0.45-0.6
Capex per share
-0.01-0.29-0.4-0.25

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.080.050.0100.02
Net income per share
-0.15-0.18-0.15-0.14-0.1
Operating cash flow per share
-0.190.63-0.03-0.1-0.1
Free cash flow per share
-0.190.43-0.03-0.1-0.1
Cash per share
0.190.350.260.150.05
Book value per share
0.710.710.480.390.29
Tangible book value per share
0.710.710.480.390.29
Share holders equity per share
0.710.710.480.390.29
Interest debt per share
0.140.140.110.10.09
Market cap
301.65M256.75M221.75M418.5M330.16M
Enterprise value
299.12M247.64M214.15M415.63M332.38M
P/E ratio
-11.89-8.15-7.49-15.21-16.18
Price to sales ratio
84.03118.82381.64.89K260.51
POCF ratio
-36.99.36-138.1-85.42-63.89
PFCF ratio
-36.5513.85-136.29-85.03-62.85
P/B Ratio
9.858.279.0921.2321.64
PTB ratio
9.858.279.0921.2321.64
EV to sales
83.33114.6368.524.86K262.27
Enterprise value over EBITDA
-43.49-31.76-33.35-74.81-78.65
EV to operating cash flow
-36.69.03-133.37-84.84-64.32
EV to free cash flow
-36.2513.36-131.62-84.45-63.27
Earnings yield
-0.02-0.03-0.03-0.02-0.02
Free cash flow yield
-0.030.07-0.01-0.01-0.02
Debt to equity
0.190.190.220.250.3
Debt to assets
0.110.120.130.140.16
Net debt to EBITDA
0.371.171.180.52-0.53
Current ratio
1.31.471.10.820.34
Interest coverage
-110.54-89.62-80.12-85.99-76.37
Income quality
1.16-4.370.220.711.01
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.131.335.9333.912.03
Research and developement to revenue
2.053.37.8142.823.17
Intangibles to total assets
00000
Capex to operating cash flow
0.01-0.320.0100.02
Capex to revenue
-0.02-4.12-0.04-0.27-0.07
Capex to depreciation
-0.0912.44-0.02-0.03-0.09
Stock based compensation to revenue
0.160.121.047.540.5
Graham number
1.541.71.261.10.8
ROIC
-0.17-0.19-0.22-0.23-0.23
Return on tangible assets
-0.12-0.15-0.17-0.19-0.18
Graham Net
-0.09-0.01-0.09-0.15-0.2
Working capital
5.08M7.1M1.37M-2M-6.08M
Tangible asset value
30.62M31.06M24.4M19.72M15.26M
Net current asset value
298K2.25M-3.24M-6.72M-9.95M
Invested capital
0.190.190.220.250.3
Average receivables
11.28M9.25M3.16M563.62K182.06K
Average payables
5.21M4.58M2.56M1.42M1.24M
Average inventory
00000
Days sales outstanding
324.48231.43118.19383.20
Days payables outstanding
542.45358.54140.87141.698.92
Days of inventory on hand
00000
Receivables turnover
0.280.390.760.230
Payables turnover
0.170.250.640.640.91
Inventory turnover
00000
ROE
-0.21-0.25-0.3-0.35-0.33
Capex per share
0-0.2000

SABS Frequently Asked Questions

What is SAB Biotherapeutics, Inc. stock symbol ?

SAB Biotherapeutics, Inc. is a US stock , located in Sioux falls of Sd and trading under the symbol SABS

Is SAB Biotherapeutics, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $3. The lowest prediction is $3 and the highest is $3

What is SABS stock prediction ?

What is SAB Biotherapeutics, Inc. stock quote today ?

SAB Biotherapeutics, Inc. stock price is $4.6 today.

Is SAB Biotherapeutics, Inc. stock public?

Yes, SAB Biotherapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap